Octreotide Acetate
Octreotide acetate is a synthetic octapeptide analog of naturally occurring somatostatin. It mimics somatostatin's inhibitory actions on growth hormone, glucagon, insulin, and gastrointestinal peptides, but has a significantly longer half-life and duration of action.
Dosage by Body Weight
Dosage is highly individualized depending on the indication (e.g., acromegaly, carcinoid syndrome, or variceal bleeding), clinical response, and tolerability. Administered via subcutaneous injection, intravenous infusion, or deep intramuscular depot injection. Pediatric use is specialized and requires close specialist supervision.
- Body Weight
- Below 5 kg
- Dose
- 1 to 5 mcg/kg/day
- Frequency
- Divided every 8 to 12 hours (subcutaneous) or as a continuous IV infusion
- Tracking Notes
- Extremely critical. Prescribed primarily in specialized neonatal units for congenital hyperinsulinism. Monitor blood glucose levels closely.
- Body Weight
- 5-7 kg
- Dose
- 5 to 35 mcg/day
- Frequency
- Divided and administered every 8 to 12 hours subcutaneously
- Tracking Notes
- Adjust doses slowly based on clinical response and endocrine markers. Watch for signs of bradycardia or gastrointestinal upset.
- Body Weight
- 8-10 kg
- Dose
- 8 to 50 mcg/day
- Frequency
- Divided and administered every 8 to 12 hours subcutaneously
- Tracking Notes
- Long-term use may cause gallbladder abnormalities (cholelithiasis). Ultrasound monitoring is advised.
- Body Weight
- 11-15 kg
- Dose
- 11 to 75 mcg/day
- Frequency
- Divided and administered every 8 to 12 hours subcutaneously
- Tracking Notes
- May impair thyroid function; periodic thyroid function tests (TFTs) are recommended.
- Body Weight
- 16-20 kg
- Dose
- 16 to 100 mcg/day
- Frequency
- Divided and administered every 8 to 12 hours subcutaneously
- Tracking Notes
- Dosing titration should be closely monitored by a pediatric endocrinologist or pediatric gastroenterologist.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 1 to 5 mcg/kg/day | Divided every 8 to 12 hours (subcutaneous) or as a continuous IV infusion | Extremely critical. Prescribed primarily in specialized neonatal units for congenital hyperinsulinism. Monitor blood glucose levels closely. |
| 5-7 kg | 5 to 35 mcg/day | Divided and administered every 8 to 12 hours subcutaneously | Adjust doses slowly based on clinical response and endocrine markers. Watch for signs of bradycardia or gastrointestinal upset. |
| 8-10 kg | 8 to 50 mcg/day | Divided and administered every 8 to 12 hours subcutaneously | Long-term use may cause gallbladder abnormalities (cholelithiasis). Ultrasound monitoring is advised. |
| 11-15 kg | 11 to 75 mcg/day | Divided and administered every 8 to 12 hours subcutaneously | May impair thyroid function; periodic thyroid function tests (TFTs) are recommended. |
| 16-20 kg | 16 to 100 mcg/day | Divided and administered every 8 to 12 hours subcutaneously | Dosing titration should be closely monitored by a pediatric endocrinologist or pediatric gastroenterologist. |
Formulation
Purpose
Used to treat acromegaly, severe diarrhea and flushing associated with metastatic carcinoid tumors, vasoactive intestinal peptide-secreting tumors (VIPomas), and to control bleeding from gastroesophageal varices.
Generic Name
Octreotide AcetateBranded Drug Names
Octreotide Acetate is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.